{"id":17434,"date":"2024-01-08T20:00:51","date_gmt":"2024-01-08T19:00:51","guid":{"rendered":"https:\/\/www.hematostat.net\/?p=17434"},"modified":"2024-01-10T20:25:43","modified_gmt":"2024-01-10T19:25:43","slug":"lancement-de-bekemv-biosimilaire-pour-le-traitement-de-lhemoglobinurie-paroxystique-nocturne-hpn-1er-biosimilaire-dans-une-maladie-rare","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/lancement-de-bekemv-biosimilaire-pour-le-traitement-de-lhemoglobinurie-paroxystique-nocturne-hpn-1er-biosimilaire-dans-une-maladie-rare\/","title":{"rendered":"Lancement de BEKEMV\u00ae, biosimilaire pour le traitement de l\u2019h\u00e9moglobinurie paroxystique nocturne (HPN), 1er biosimilaire dans une maladie rare."},"content":{"rendered":"<p>Amgen France annonce le lancement de BEKEMV\u00ae (eculizumab, ABP 959) dans le traitement de l&#8217;h\u00e9moglobinurie paroxystique nocturne (HPN) chez l&#8217;adulte et l&#8217;enfant. Il s\u2019agit du premier biosimilaire approuv\u00e9 dans le traitement d\u2019une maladie rare. Inscrit sur la liste des m\u00e9dicaments remboursables depuis le 22 septembre 2023, BEKEMV\u00ae vient compl\u00e9ter le portefeuille des 3 autres biosimilaires d\u2019Amgen en France.<\/p>","protected":false},"excerpt":{"rendered":"<p>Amgen France annonce le lancement de BEKEMV\u00ae (eculizumab, ABP 959) dans le traitement de l&#8217;h\u00e9moglobinurie paroxystique nocturne (HPN) chez l&#8217;adulte et l&#8217;enfant. Il s\u2019agit du premier biosimilaire approuv\u00e9 dans le [&hellip;]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[441],"class_list":["post-17434","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-admin6779"],"aioseo_notices":[],"authors":[{"term_id":441,"user_id":1,"is_guest":0,"slug":"admin6779","display_name":"HematoStat.net","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/4f64711e55fa3c9401676697c4783cec15305a6f940a0f120048b6141a611347?s=96&d=mm&r=g","first_name":"HematoStat.net","last_name":"","user_url":"http:\/\/www.hematostat.net","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/17434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=17434"}],"version-history":[{"count":1,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/17434\/revisions"}],"predecessor-version":[{"id":17435,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/17434\/revisions\/17435"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=17434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=17434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=17434"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=17434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}